JENA, Germany and DUBLIN, Calif.—Carl Zeiss Meditec AG announced that after securing all required regulatory approvals, it has completed the acquisition of 100 percent of D.O.R.C. (Dutch Ophthalmic Research Center) from the investment firm Eurazeo SE, Paris, France. The acquisition enhances and complements Zeiss Medical Technology's broad ophthalmic portfolio and range of digitally connected workflow solutions for addressing a wide variety of eye conditions, spanning retina and cornea disorders, cataract, glaucoma, and refractive errors, according to the announcement. VMAIL first reported on the agreement back in December.

With the acquisition, Zeiss will expand its position in the vitreo-retinal (VR) surgery segment and strengthen its position as a growing manufacturer of ophthalmic medical devices globally, according to the statement. D.O.R.C.’s products are used by ophthalmic surgeons around the world to treat a wide range of vision-threatening conditions. Their portfolio of devices, disposables and liquids for ophthalmic surgeries are a complement to the Zeiss Medical Technology portfolio.

"Today holds significant importance for us as we bring our teams together and turn our collective attention toward delivering breakthrough innovations and solutions for our customers," said Dr. Markus Weber, president and CEO of Carl Zeiss Meditec AG. "We are very excited to welcome D.O.R.C.'s team members to our Zeiss family and to begin integrating our products and practices as we work toward a brighter future together."

“With D.O.R.C., we have an incredible opportunity to serve ophthalmologists around the world with more complete workflows and solutions than ever before," said Euan S. Thomson, PhD, president of ophthalmology and head of the digital business unit for Zeiss Medical Technology. "We've set our sights high to become the top player in the world for ophthalmology by leveraging our workflow solutions, enhancing our portfolio offerings and market position in the anterior surgery segment, and by significantly expanding our presence in the posterior surgery segment."

“With four decades behind our amazing business and surgeon-inspired innovation, we look forward to writing the next chapter of our success story together with Zeiss Medical Technology," said Pierre Billardon, CEO of D.O.R.C. "By joining forces, we can extend our reach, scale our efforts, and accelerate ophthalmic surgery advancements for more surgeons faster than before. I am filled with a great sense of pride and gratitude for every D.O.R.C. team member. Together, we have achieved so much to arrive at this pivotal moment in our journey. And together with Zeiss, we have so much more to accomplish in our bright future ahead to help patients see again."

With the completion of this acquisition, health care professionals can expect to benefit from an extensive and unique combination of digitally connected devices and workflow solutions, from clinical pre-operative needs to the surgical operating room, according to the companies. The two companies' immediate priorities span maintaining business continuity and customer satisfaction, cultivating areas of deep expertise, and enhancing the value of their solutions and services for current and future customers.